Neuroimagen y neurotoxicidad inducida por MDMA (éxtasis)

Una D. McCann, George A. Ricaurte

Resumen


El incremento del consumo de éxtasis (MDMA) por parte de los jóvenes ha obligado al estudio de efectos a corto y medio plazo sobre el SNC. En la última década, se demostró la existencia de neurotoxicidad serotoninérgica en el SNC. Recientemente aparecieron estudios tendentes a demostrar también daño dopaminérgico que se ha evidenciado en experimentación animal. Las diferentes técnicas de neuroimagen han contribuido a estos hallazgos, a través del estudio de flujo como del nivel de captaciones en los distintos sistemas receptoriales implicados, tanto presinápticos como postsinápticos. Los resultados que se compilan proceden de los trabajos de neurotoxicidad más relevantes realizados a través de las diferentes técnicas de neuroimagen (SPECT, PET, MRS, MRI de difusión y perfusión). Se concluye que existe suficiente demostración, en diferentes especies animales, incluidos primates, de que la MDMA produce neurotoxicidad serotoninérgica y dopaminérgica y que existen resultados clínicos que confirman estos hallazgos en humanos.


Palabras clave


éxtasis; MDMA; neurotoxicidad; neuroimagen

Texto completo:

PDF

Referencias


Brett M, Johnsrude IS, Owen AM. The problem of functional localization in the human brain. Nat Rev Neurosci 2002; 3: 243-249.

Buchert R, Thomasius R, Nebeling B, Petersen K, Obrocki J, Jenicke L, Wilke F, Wartberg L, Zapletalova P, Clausen M. Long-Term effects of "Ecstasy" use on serotonin transporters of the brain investigated by PET. J Nucl Med 2003; 44: 375-384.

Buchert R, Obrocki J, Thomasius R, Vaterlein O, Petersen K, Jenicke L, Bohuslavizki KH, Clausen M. Long-term effects of 'ecstasy' abuse

on the human brain studied by FDG PET. Nucl Med Commun 2001; 22: 889-897.

Calne DB, Langston JW, Martin W, Stoessel A, Ruth T, Adam M, Schulzer M. Positron emission tomography after MPTP: observations

relating to the cause of Parkinson's disease. Nature 1985; 317: 246-248.

Chang L, Grob CS, Ernst T, Itti L, Mishkin FS, Jose-Melchor R, Poland RE. Effect of ecstasy [3,4-methylenedioxymethamphetamine (MDMA)]

on cerebral blood flow: a co-registered SPECT and MRI study. Psychiatry Res 2000; 98: 15-28.

Chang L, Ernst T, Grob CS, Poland RE. Cerebral (1)H MRS alterations in recreational 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users. J Magn Reson Imaging 1999; 10: 521-526.

Christophersen AS. Amphetamine designer drugs - an overview and epidemiology. Toxicol Lett 2000; 112-113: 127-131.

Gamma A, Buck A, Berthold T, Vollenweider FX. No difference in brain activation during cognitive performance between ecstasy (3,4-methylenedioxymethamphetamine) users and control subjects: a [H2(15)O]-positron emission tomography study. J Clin Psychopharmacol 2001; 21: 66-71.

Hilton J, Yokoi F, Dannals RF, Ravert HT, Szabo Z, Wong DF. Column-switching HPLC for the analysis of plasma in PET imaging studies.

Nucl Med Biol 2000; 27: 627-630.

Houle S, Ginovart N, Hussey D, Meyer JH, Wilson AA. Imaging the serotonin transporter with positron emission tomography: initial human studies with [11C]DAPP and [11C]DASB. Eur J Nucl Med 2000; 27: 1719-1722.

Johnston LD, O’Malley PM, Bachman JG. Monitoring the Future national survey results on drug use, 1975-2000. Volume I: Secondary school students (NIH Publication No. 01- 4924). Bethesda, MD: National Institute on Drug Abuse, 2001a.

Johnston LD, O’Malley PM, Bachman JG. Monitoring the Future national survey results on drug use, 1975-2000. Volume 2: College students and adults ages 19-40 (NIH Publication No. 01-4925). Bethesda, MD: National Institute on Drug Abuse, 2001b.

Lew R, Malberg JE, Ricaurte GA, Seiden LS. Evidence for and mechanism of action of neurotoxicity of amphetamine related compounds. En: Highly Selective Neurotoxins: Basic and Clinical

Applications, Kostrzewa RM, (ed), Humana Press Inc., Totowa, pp. 235-268, 1997.

McCann UD, Ricaurte GA, Molliver ME. "Ecstasy" and serotonin neurotoxicity: new findings raise more questions. Arch Gen Psychiatry 2001; 58: 907-908.

McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA. Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy")

on brain serotonin neurons in human beings. Lancet 1998; 352: 1433-1437.

Meyer JH, Wilson AA, Ginovart N, Goulding V, Hussey D, Hood K, Houle S. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [11C]DASB

PET imaging study. Am J Psychiatry 2001; 158: 1843-1849.

Obergriesser T, Ende G, Braus DF, Henn FA. Hippocampal 1H-MRSI in ecstasy users. Eur Arch Psychiatry Clin Neurosci 2001; 251: 114-116.

Obrocki J, Schmoldt A, Buchert R, Andresen B, Petersen K, Thomasius R. Specific neurotoxicity of chronic use of ecstasy. Toxicol Lett 2002; 127: 285-297.

Obrocki J, Buchert R, Vaterlein O, Thomasius R, Beyer W, Schiemann T. Ecstasy--long-term effects on the human central nervous system

revealed by positron emission tomography. Br J Psychiatry 1999; 175:186-188.

Parrott AC, Lees A, Granham NJ, Jones M, Wesnes K. Cognitive performance in recreational users of MDMA or “ecstasy”: evidence for memory deficits. J Psychopharmacol 1998; 12: 79-83.

Parrott AC, Buchanan T, Scholey AB, Heffernan T, Ling J, Rodgers J. Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users. Hum Psychopharmacol 2002; 17: 309-312.

Reneman L, Booij J, Majoie CB, Van Den Brink W, Den Heeten GJ. Investigating the potential neurotoxicity of Ecstasy (MDMA): an imaging approach. Hum Psychopharmacol 2001; 16:579-588.

Reneman L, Booij J, Habraken JB, De Bruin K, Hatzidimitriou G, Den Heeten GJ, Ricaurte GA. Validity of [123I]beta-CIT SPECT in detecting

MDMA-induced serotonergic neurotoxicity. Synapse 2002; 46: 199-205.

Reneman L, Booij J, Lavalaye J, de Bruin K, Reitsma JB, Gunning B, den Heeten GJ, van Den Brink W. Use of amphetamine by recreational users of ecstasy (MDMA) is associated with reduced striatal dopamine transporter densities: a [123I]beta-CIT SPECT study--preliminary report. Psychopharmacology (Berl) 2002;

: 335-340.

Reneman L, Endert E, de Bruin K, Lavalaye J, Feenstra MG, de Wolff FA, Booij J. The acute and chronic effects of MDMA ("ecstasy") on cortical 5-HT2A receptors in rat and human brain. Neuropsychopharmacology 2002; 26:387-396.

Reneman L, Booij J, de Bruin K, Reitsma JB, de Wolff FA, Gunning WB, den Heeten GJ, van den Brink W. Effects of dose, sex, and longterm abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet 2001; 358: 1864-1869.

Reneman L, Lavalaye J, Schmand B, de Wolff FA, van den Brink W, den Heeten GJ, Booij J. Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4- methylenedioxymethamphetamine (MDMA or "ecstasy"): preliminary findings. Arch Gen Psychiatry 2001; 58: 901-906.

Reneman L, Majoie CB, Habraken JB, den Heeten GJ. Effects of ecstasy (MDMA) on the brain in abstinent users: initial observations with diffusion and perfusion MR imaging. Radiology 2001; 220: 611-617.

Reneman L, Booij J, Schmand B, van den Brink W, Gunning B. Memory disturbances in "Ecstasy" users are correlated with an altered brain serotonin neurotransmission. Psychopharmacology

(Berl) 2000; 148: 322-324.

Reneman L, Habraken JB, Majoie CB, Booij J, den Heeten GJ. MDMA ("Ecstasy") and its association with cerebrovascular accidents: preliminary findings. AJNR Am J Neuroradiol 2000; 21: 1001-1007.

Ricaurte GA, Yuan J, McCann UD. (")3,4 Methylenedioxymethamphetamine (MDMA, “Ecstasy”)-induced serotonin-neurotoxicity: Studies in animals. Neuropsychobiol 2000; 42: 5-10.

Ricaurte GA, Yuan J, Hatzidimitriou G, Cord Branden J, McCann Una D: Severe dopaminergic neurotoxicity in primates given typical recreational doses of MDMA (“Ecstasy”). Science 2002 ; 297: 2260-2263.

Ricaurte GA, McCann UD. Assessing long-term effects of MDMA (Ecstasy). Lancet 2001; 358:1831-1832.

Ricaurte GA, McCann UD, Szabo Z, Scheffel U. Toxicodynamics and long-term toxicity of the recreational drug, 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'). Toxicol Lett

; 112-113: 143-146.

Rogers RD, Robbins TW. Investigating the neurocognitive deficits associated with chronic drug misuse. Curr Opin Neurobiol 2001; 11: 250-257.

Scheffel U, Lever JR, Stathis M, Ricaurte GA. Repeated administration of MDMA causes transient down-regulation of 5-HT2 receptors. Neuropharmacology 1992; 31: 881-893.

Scheffel U, Szabo Z, Mathews WB, Finley PA, Dannals RF, Ravert HT, Szabo K, Yuan J, Ricaurte GA. In vivo detection of short- and long-term MDMA neurotoxicity--a positron emission tomography study in the living baboon brain. Synapse 1998; 29: 183-192.

Schreckenberger M, Gouzoulis-Mayfrank E, Sabri O, Arning C, Tuttass T, Schulz G, Kaiser HJ, Wagenknecht G, Sass H, Bull U. [Investigations on the effect of "ecstasy" on cerebral glucose

metabolism: an 18-FDG PET study]. Nuklearmedizin 1998; 37: 262-267.

Seiden LS, Ricaurte GA: Neurotoxicity of methamphetamine and related drugs. En: Psychopharmacology - A Generation of Progress, Meltzer HY (ed). Raven Press, NY, pp. 359-366, 1987.

Sharkey J, McBean DE, Kelly PA. Alterations in hippocampal function following repeated exposure to the amphetamine derivative methylenedioxymethamphetamine ("Ecstasy"). Psychopharmacology

(Berl) 1991; 105: 113-118.

Semple DM, Ebmeier KP, Glabus MF, O'Carroll RE, Johnstone EC. Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ('ecstasy') users. Br J Psychiatry 1999; 175: 63-69.

Suehiro M, Scheffel U, Dannals RF, Ravert HT, Ricaurte GA, Wagner HN Jr. A PET radiotracer for studying serotonin uptake sites: carbon-11-McN-5652Z. J Nucl Med 1993; 34: 120-127.

Szabo Z, McCann UD, Wilson AA, Scheffel U, Owonikoko T, Mathews WB, Ravert HT, Hilton J, Dannals RF, Ricaurte GA. Comparison of (+)-

(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions. J Nucl Med 2002; 43: 678-692.

Wilson AA, Ginovart N, Schmidt M, et al. Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, and in vitro and ex vivo evaluation of (11)C-labeled 2-(phenylthio)araalkyl amines. J Med Chem 2000; 43: 3103-3110.

Yamada K, Kizu O, Mori S, Ito H, Nakamura H, Yuen S, Kubota T, Tanaka O, Akada W, Sasajima H, Mineura K, Nishimura T. Brain Fiber Tracking with Clinically Feasible Diffusion-Tensor MR Imaging: Initial Experience. Radiology 2003; 227: 295-301.




DOI: https://doi.org/10.20882/adicciones.456

Enlaces refback

  • No hay ningún enlace refback.